Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$131.82 USD

131.82
735,572

-0.48 (-0.36%)

Updated May 10, 2024 04:00 PM ET

After-Market: $131.94 +0.12 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

    Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD

    Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).

      Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

      We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

        Sarepta Appoints Ex-Allergan Executive as CEO and President

        Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

          Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

          Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased

            Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock?

            Investors in Sarepta Therapeutics, Inc. (SRPT) need to pay close attention to the stock based on moves in the options market lately.

              Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?

              Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

                We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

                  Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow

                  Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.

                    Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options

                    Options traders are pricing in a big move for Sarepta Therapeutics (SRPT) shares as it has huge implied volatility.

                      Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?

                      Sarepta Therapeutics is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                        Catabasis Hits 52-Week Low on Poor DMD Drug Study Data

                        Catabasis (CATB) announced disappointing top-line safety and efficacy data from part B of the MoveDMD study (phase I/II) on edasalonexent (CAT-1004).

                          Is BioMarin (BMRN) Well Poised for Growth in 2017?

                          We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

                            Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?

                            Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

                              Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks

                              The biotech sector continues to witness a flurry of mergers and acquisitions and licensing deals.